Gehrke Brenda J, Chefer Vladimir I, Shippenberg Toni S
Integrative Neuroscience Section, NIH/NIDA Intramural Research Program, Baltimore, MD 21224, USA.
Psychopharmacology (Berl). 2008 Apr;197(3):509-17. doi: 10.1007/s00213-007-1067-6. Epub 2008 Feb 2.
Acute systemic administration of salvinorin A, a naturally occurring kappa-opioid receptor (KOPr) agonist, decreases locomotion and striatal dopamine (DA) overflow.
Conventional and quantitative microdialysis techniques were used to determine whether salvinorin A infusion into the dorsal striatum (DSTR) decreases DA overflow by altering DA uptake or release. The influence of repeated salvinorin A administration on basal DA dynamics and cocaine-evoked alterations in DA overflow and locomotion was also assessed.
Salvinorin A was administered via the dialysis probe (0; 20-200 nM) or via intraperitoneal (i.p.) injection (1.0 or 3.2 mg/kg per day x 5 days). The effects of a challenge dose of cocaine were examined 48 h after repeated salvinorin treatment.
Retrodialysis of salvinorin A produced a dose-related, KOPr antagonist reversible, decrease in DA levels. Extracellular DA levels were decreased whereas DA extraction fraction, which provides an estimate of DA uptake, was unaltered. In contrast to its acute administration, repeated salvinorin A administration did not modify dialysate DA levels. Similarly, neither basal extracellular DA levels nor DA uptake was altered. Unlike synthetic KOPr agonists, prior repeated administration of salvinorin A did not attenuate the locomotor activating effects of an acute cocaine (20 mg/kg, i.p.) challenge. However, cocaine-evoked DA overflow was enhanced.
These data demonstrate that acute, but not repeated, salvinorin A administration decreases mesostriatal neurotransmission and that activation of DSTR KOPr is sufficient for this effect. Differences in the interaction of salvinorin and synthetic KOPr agonists with cocaine suggest that the pharmacology of these agents may differ.
天然存在的κ-阿片受体(KOPr)激动剂沙维诺林A的急性全身给药可降低运动能力和纹状体多巴胺(DA)溢出。
采用传统和定量微透析技术,确定向背侧纹状体(DSTR)注入沙维诺林A是否通过改变DA摄取或释放来降低DA溢出。还评估了重复给予沙维诺林A对基础DA动力学以及可卡因诱发的DA溢出和运动变化的影响。
通过透析探针(0;20 - 200 nM)或腹腔注射(i.p.)(每天1.0或3.2 mg/kg,共5天)给予沙维诺林A。在重复沙维诺林治疗48小时后,检测挑战剂量可卡因的效果。
逆向透析沙维诺林A导致DA水平呈剂量相关的、KOPr拮抗剂可逆性降低。细胞外DA水平降低,而提供DA摄取估计值的DA提取分数未改变。与急性给药不同,重复给予沙维诺林A并未改变透析液DA水平。同样,基础细胞外DA水平和DA摄取均未改变。与合成KOPr激动剂不同,预先重复给予沙维诺林A并未减弱急性可卡因(20 mg/kg,i.p.)挑战引起的运动激活作用。然而,可卡因诱发的DA溢出增强。
这些数据表明,急性而非重复给予沙维诺林A可降低中脑纹状体神经传递,并且DSTR KOPr的激活足以产生这种效果。沙维诺林与合成KOPr激动剂与可卡因相互作用的差异表明这些药物的药理学可能不同。